Conv. Plasma
Nigella Sativa
Vitamin A
Vitamin C
Vitamin D

Home   COVID-19 treatment studies for Bamlanivimab  COVID-19 treatment studies for Bamlanivimab  C19 studies: Bamlanivimab  Bamlanivimab   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption (RCT)74%0.26 [0.09-0.75]hosp.5/3099/143Improvement, RR [CI]TreatmentControlGottlieb (RCT)71%0.29 [0.09-0.96]hosp./ER4/1017/52Lilly (DB RCT)92%0.08 [0.00-1.43]death0/5114/258Webb80%0.20 [0.03-1.46]death1/47957/5,536Tau​2 = 0.00; I​2 = 0.0%Early treatment76%0.24 [0.12-0.50]10/1,40077/5,98976% improvementACTIV-3/T.. (RCT)-100%2.00 [0.69-5.83]death9/1635/151Improvement, RR [CI]TreatmentControlBariola67%0.33 [0.10-1.01]death4/23412/234Tau​2 = 1.30; I​2 = 80.7%Late treatment18%0.82 [0.14-4.77]13/39717/38518% improvementLilly (RCT)57%0.43 [0.28-0.67]symp. case483 (n)482 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP57%0.43 [0.28-0.67]0/4830/48257% improvementAll studies59%0.41 [0.23-0.74]23/2,28094/6,85659% improvement7 bamlanivimab COVID-19 Oct 27, 2021Tau​2 = 0.25; I​2 = 46.8%; Z = 3.00Effect extraction pre-specifiedFavors bamlanivimabFavors control
Database of all bamlanivimab COVID-19 studies. Submit updates/corrections.
Jun 23
Early Webb et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab331 (Peer Reviewed)
death, ↓79.7%, p=0.09
Real-World Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early COVID-19
Details   Retrospective 479 patients treated with bamlanivimab showing lower mortality, hospital admission, and emergency department visits with treatment. Authors falsely state that "no other COVID-19 therapies for ambulatory patients have pr..
May 18
N/A Focosi et al., Research Square, doi:10.21203/ (Preprint) Emergence of SARS-CoV-2 Spike Escape Mutation Q493r After Bamlanivimab/Etesevimab Treatment for COVID-19
Details   Case study showing that a mutation resistant to both bamlanivimab and etesevimab can arise in vivo. Authors note that accelerated evolution can occur under selective pressure from therapeutic interventions with neutralizing antibodies, an..
Mar 30
Late Bariola et al., medRxiv, doi:10.1101/2021.03.25.21254322 (Preprint)
death, ↓66.8%, p=0.05
Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection
Details   Retrospective 234 patients receiving bamlanivimab and 234 matched controls, showing lower hospitalization and mortality with treatment. Greater benefit was seen with administration within 4 days of their positive COVID-19 test.
Mar 10
Early Lilly, Press Release (Preprint)
death, ↓92.3%, p=0.01
Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
Details   Results from the BLAZE-1 study of combined bamlanivimab/etesevimab, showing significantly lower mortality and combined mortality/hospitalization with treatment.
Jan 21
PrEP Lilly, Press Release (Preprint)
symp. case, ↓57.0%, p=0.0002
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
Details   Press release on the BLAZE-2 trial at nursing homes showing significantly lower symptomatic COVID-19 with treatment.
Jan 21
Early Gottlieb et al., JAMA, doi:10.1001/jama.2021.0202 (Peer Reviewed)
hosp./ER, ↓70.6%, p=0.05
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
Details   RCT for LY-CoV555 monotherapy and LY-CoV555/LY-CoV016 combination therapy with 592 patients showing lower hospitalization/ER visits with treatment. For viral load at day 11, a statistically significant reduction was found with combinatio..
Dec 22
Late ACTIV-3/TICO LY-CoV555 study group, NEJM, doi:0.1056/NEJMoa2033130 (Peer Reviewed)
death, ↑100%, p=0.22
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
Details   Late stage RCT of LY-CoV555 added to remdesivir, showing non-statistically significant higher mortality with the addition of LY-CoV555.
Oct 28
Early Chen et al., NEJM, doi:10.1056/NEJMoa2029849 (Peer Reviewed)
hosp., ↓74.3%, p=0.02
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Details   Interim analysis of the BLAZE-1 phase 2 trial of outpatients showing lower hospitalization or ER visits (1.6% versus 6.3%), and improvements in symptoms and viral load compared to placebo. NCT04427501
Oct 26
News Lilly, Press Release (News)
Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial
Details   ACTIV-3 intermin analysis shows LY-CoV555 is unlikely to help hospitalized patients. ACTIV-2, BLAZE-1 and BLAZE-2 trials remain ongoing.
Oct 7
Early Lilly, Press Release (Preprint)
hosp., ↓84.5%, p=0.05
SARS-CoV-2 neutralizing antibody program update
Details   Interim results from the BLAZE-1 outpatient RCT showing improvements in viral load, symptoms and hospitalization. Combination therapy significantly reduced viral load at day 11 (p=0.011). A greater effect is seen at day 7 (p<0.001). The ..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.